

## WOW WOMAN OF THE WEEK PODCAST SERIES

OCTOBER

**Jody Casey**, VP of Healthcare Partnerships,  
Elligo Health Research

**Amanda Powers-Han**, Senior Partner,  
Media, Greater Than One

**Sandra Pelletier**, CEO, Evofem  
Biosciences

**Dr. Helen Hyun Jung Lee**, President and  
CEO, Samyang Pharmaceuticals USA

Sponsored by Elligo Health Research

## Astellas ALL IN ON GENE THERAPY

In October, the new Astellas Institute for Regenerative Medicine was opened in Boston; it's one of the most comprehensive regenerative medicine centers in the industry. The 262,000-square-foot facility will be home to more than 150 researchers and one of the industry's largest stem-cell libraries and embodies the commitment Astellas has made to developing leading gene therapies. Over the last few years, Astellas made several acquisitions to bolster its capabilities, including Ocata Therapeutics, one of the earliest biotechs developing stem cell therapies under the leadership of stem cell pioneer Dr. Robert Lanza; Universal Cells (Seattle) with a unique technology to produce pluripotent stem cells that have lower immunological rejection to create allogeneic therapies, or off-the-shelf cell therapies, to open the door to treat, and even cure, a wide range of diseases; and Xyphos Biosciences (South San Francisco), with synthetic biology methods to adapt cell therapies with flexibility, increase control, and improve safety, representing techniques for state-of-the-art CAR-T cells as well as stem cell applications.

## #NoGOINGBACK

Almost three dozen signatory companies collaborated to form the #NoGoingBack movement, which is committed to continuing the progress made in clinical research during the COVID-19 pandemic. According to the movement, the industry has learned bold new ways to conduct trials due to COVID-19, and now that we have seen the future so clearly, there is no going back. They are encouraging everyone, whether you work at a sponsor, site, provider, advocacy group, or other healthcare organization, to join in the mission to keep trials moving forward. By making a pledge your name will be posted in support of #NoGoingBack:

**I PLEDGE** to honor the lessons we've learned and progress we've made in clinical trials:

- ▶ We can adapt faster than we thought we could.
- ▶ Collaboration between "competitors" is needed to accelerate.
- ▶ Our industry has an unparalleled opportunity, to make huge improvements in drug development.
- ▶ Patients deserve and want flexible options for trial participation.

**I PLEDGE** to maintain the momentum we gained from new ideas, partnerships, and technology that help us advance life-changing treatments faster.



**I PLEDGE** to keep moving forward and that I will never be satisfied with going back to trial conduct of the past.

**I PLEDGE** to share this charter with my colleagues and peers, and encourage them to pledge to preserve the progress we've made in clinical trials.

The chairpersons of #NoGoingBack are: Craig Lipset, advisor and founder of Clinical Innovation Partners; Allyson Small, chief operating officer, SCRS; Scott Connor, chief marketing officer, Signant Health; Maima Karmo, president and CEO, Tigerlily Foundation; and Sung Poblete, CEO, Stand up to Cancer.

For more information, visit <https://www.nogoingback.health/>

## BioNJ's COMPANY and PITCH COMPETITION

BioNJ announced the winners of its 2020 Company and Pitch Presentation Competition held in conjunction with the organization's 10th Annual BioPartnering Conference held in October. Presented in concert with J.P. Morgan and Johnson & Johnson Innovation, the conference brought together life-sciences professionals from 11 countries and 24 states as well as the District of Columbia and featured more than 80 company and pitch presentations, including a record number of 21 women leaders who presented on behalf of their companies, hundreds of 1:1 partnering meetings, plenary sessions led by industry leaders, posters, exhibits and presentations by world-renowned research institutions from the region.

### The 2020 Company and Pitch Presentation Award Honorees are:

#### Public Company:

**Marco Taglietti**, M.D., President & CEO, Scynexis Inc.

#### Later Stage Investor-Financed Company:

**Heather Franklin**, President and CEO, Blaze Bioscience Inc.

#### Private Company:

**Raymond Houck**, CEO, Aclipse Therapeutics

#### Institution Spin-Out Pitch:

**Robert Scribner**, CEO, Respirogen Inc.

#### Start-Up Pitch:

**Irena Volkov**, Founder and CEO, Surgicure Technologies Inc.

"We couldn't be more excited for these entrepreneurs or more pleased with the outcome of the conference," says BioNJ President and CEO Debbie Hart. "In its 10th year, despite being virtual, BioNJ's BioPartnering Conference once again delivered an energetic atmosphere which fostered collaboration, learning and mentorship."

DIGITAL INFLUENCER PROFILES

Getting personal with the digital experts who are influencing the future of the life sciences

The **Digital Influencer Profile** program is a unique way to feature your company's digital thought leader(s). These experts are significantly moving the technology needle to improve the experience of your organization's employees, customers, suppliers, partners, and stakeholders. From R&D to commercialization, these influencers have their finger on the pulse of the current and future trends that are expected to transform the industry. In an exclusive interview with a **PharmaVOICE** editor, your expert will discuss his or her approaches to digital strategies, processes, and engagement.



► **Bonus Offer:** Receive a free **One-on-One Video** recorded virtually... this is a \$2,250 value!

►► **Added Value**

**\$3,900 in added value included in the program**

PDF file of unit - \$600 value

Appears within the Featured Contributed Content section on the PharmaVOICE.com homepage for 30 days - \$300 value

Content box on an eNewsletter \$1,000 value

The unit appears in the digital edition of PharmaVOICE with a hyperlink to your URL - \$2,000 value

Each profile page will include your thought leader's photo, name, title, and company. Photos need to be high-resolution, four-color, minimum 300 dpi. In the case a one-on-one interview can't be coordinated, written responses to a tailored question set can be provided via email. Written responses should be approximately 250-300 words - inclusive of all questions. Profiles will be designed using the company's logo and branding and will be provided in PDF format for review before publication.

For more details or to place an advertisement, contact Lisa Backet, Publisher, at 609-730-0196 or lbacket@pharmavoiced.com or Suzanne Besse at 561-465-5102 or sbesse@pharmavoiced.com.



## EVERSANA™ Eversana NAMED GREAT PLACE TO WORK

Building on its momentum as a pioneer of next-generation commercialization services to the life sciences industry, Eversana has again been certified as a Great Place to Work, for the second consecutive year, by the global authority in workplace culture.

Eversana was named to the prestigious list, based on feedback from an anonymous survey by the company's more than 3,000 employees.

"To receive this recognition during a year like 2020 speaks to the culture we work so hard to create every day," says Jim Lang, CEO, Eversana. "We will always invest the time and resources to create a best-in-class workplace that creates best-in-class support for our employees, clients and patients."

The Great Place to Work recognition, which measures companies against organizations of similar size and industry, provides a valuable benchmark for employees and reinforces the company's commitment to retaining and attracting the best talent to serve its clients worldwide.

## Aditum BIO LAUNCHES TEMPERO BIO

Aditum Bio has launched Tempero Bio, a spin-out that focuses on developing an advanced neuroscience drug, TMP-301, to treat addiction and anxiety as part of Aditum Bio's mission to bring medical innovation to highly prevalent diseases. The urgent need to treat addiction and anxiety has increased due to the pandemic, with Americans three times more likely to report anxiety symptoms than in 2019, according to the CDC, and 13% of Americans reporting increased drinking or drug use — the ripple effect of these increases could impact public health for years to come.

Aditum Bio is the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis



Joe Jimenez



Dr. Mark Fishman

Institutes for BioMedical Research (NIBR) Dr. Mark Fishman. Tempero Bio is the second independent company launched by Aditum Bio, whose mission is to give large patient populations access to medicines which otherwise may not be developed.

## BioCentriq OPENS IN NEW JERSEY

The New Jersey Innovation Institute (NJII) and Choose New Jersey hosted a virtual ribbon cutting, facility tour, and panel discussions to mark the opening of BioCentriq, NJII's cutting-edge cell and gene therapy development and clinical manufacturing center located on the campus of the New Jersey Institute of Technology (NJIT) in Newark, N.J.

"BioCentriq's mission is to bring together industry, technology developers, academia, and regulatory agencies to help advance the development and manufacturing of cell and gene therapies," says Haro Hartounian, Ph.D., senior VP and GM of the biopharma division, and senior VP and general manager of BioCentriq. "We are thrilled to open the doors to our center at a time when demand for process development and clinical manufacturing of cell and gene therapies exceeds capacity available from existing contract development and manufacturing organizations. Our goal is to provide a collaborative space where innovative approaches and technologies can be utilized to help make emerging therapeutics available to the patients that so desperately need them."

to help make emerging therapeutics available to the patients that so desperately need them."



Caption: BioCentriq Ribbon Cutting at NJIT Life Sciences & Engineering Center Building in Newark, N.J., from left to right are: Robert Cohen, president, digital, robotics, and enabling technology, Stryker, Simon Nynens, CEO, New Jersey Innovation Institute (NJII), Joel Bloom, Ed.D., president, New Jersey Institute of Technology (NJIT), Dan Wessner, director of sales, Pall Biotech, Haro Hartounian, Ph.D., senior VP and general manager, NJII, Fadi P. Deek, Ph.D., provost and senior executive VP, NJIT, and Jose Lozano, president & CEO, Choose New Jersey.

### 2021 Therapeutic Digests

- ▶ **January:** Diabetes
- ▶ **February:** Digital Therapeutics
- ▶ **March:** Endocrinology
- ▶ **April:** Immunization and Vaccines
- ▶ **May:** Cardiology
- ▶ **June:** Oncology
- ▶ **July:** Dermatology
- ▶ **August:** Arthritis and Other Inflammatory Diseases
- ▶ **September:** Gene Therapy for Rare Disorders
- ▶ **October:** Neurology
- ▶ **November:** Infectious Disease — update on COVID-19
- ▶ **December:** Pulmonology & Respiratory Medicine

## PHARMAVOICE.COM

**CONTRIBUTED ARTICLES:**

» **Modern Medical Affairs: Embracing Digital Agility and Customer Centricity**

**Provided By:** Indegene

» **Indegene Digital Summit 2020 Set to be the North Star for Dialogues on Digital Acceleration in Life Sciences**

**Provided By:** Indegene

» **Changing Landscape of Clinical Trials Data Capture and Reporting during COVID-19 Pandemic**

**Provided By:** Indegene

**EBOOK:**

» **Innovating for the Future of Drug Development**

**Sponsored by:** Parexel

**PODCASTS:**

» **How Do You Launch a Therapy for an Ultra-Rare Disease?**

**Sponsored by:** Fishawack Health

» **Unmet Needs with Traditional Patient Support Programs**

**Sponsored by:** Mango Health, a TrialCard company

» **The Pandemic's Impact on Patient Assistance Programs: TrialCard's TC Script Leads the Way**

**Sponsored by:** TrialCard

» **Using Virtual Engagement to Improve HCP Access and Drive Brand Performance**

**Sponsored by:** TrialCard

**THERAPEUTIC DIGESTS:**

» **CNS**

**Provided by:** ThinkGen and PharmaVOICE

» **Digital Therapeutics**

**Provided by:** ThinkGen and PharmaVOICE

» **Women's Health**

**Provided by:** ThinkGen and PharmaVOICE

**VIDEOS:**

» **The ABC's of Digital Health — Part 1: A Data Led Approach**

**Sponsored by:** PRA Health Sciences

» **The ABC's of Digital Health — Part 2: Better Patient Journey**

**Sponsored by:** PRA Health Sciences

» **The ABC's of Digital Health — Part 3: Clinical Search Simplified**

**Sponsored by:** PRA Health Sciences

**WEBINARS/VIRTUAL PANELS:**

» **Why Centralizing Medical Imaging File Capture & Adjudication Enhances Decision Making**

**Sponsored by:** Datatrak International

» **Silicone Layer in Glass Primary Packaging: Stability and Optimization Through a Combined Approach of Mathematical Modeling and Experimental DOEs**

**Sponsored by:** Stevanato Group

» **(On Demand) The Future of HCP Engagement**

**Sponsored by:** Avant Healthcare

» **(On Demand) The State of Product Launch During and Post-COVID-19**

**Sponsored by:** Guidehouse

» **(On Demand) Using EMR RWE to Improve Clinical Research and Patient Enrollment**

**Sponsored by:** Inteliquet

» **(On Demand) 2020 State of the State: Copay and Patient Affordability**

**Sponsored by:** IQVIA

» **(On Demand) Finding the best partner for your biotech – Optimizing study design, partnering, and identifying investors**

**Sponsored by:** Parexel International

**WHITE PAPERS:**

» **Come Together — How HCP-Focused Social Media Platforms are Integral to the Future of Medical Education**

**Provided By:** Avant Healthcare

» **Engaging HCPs in A Virtual World**

**Provided By:** ArcheMedX

» **Critical Changes to Co-Pay Assistance Programs in 2021: What Biopharmaceutical Manufacturers Need to Know**

**Provided By:** TrialCard